Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779276 | 1.00 | TSHR (0.54) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL1499496 | 1.00 | TSHR (0.54) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL7815997 | 0.85 | HTR2C (0.41) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL21974861 | 0.84 | TSHR (0.67) | TSHRPARP1MEN1KMT2AGSTO1 | |
| SCHEMBL46283 | 0.84 | TSHR (0.67) | TSHRPARP1MEN1KMT2AGSTO1 | |
| SCHEMBL12186571 | 0.81 | DRD2 (0.50) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL12186575 | 0.81 | DRD2 (0.50) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL15154742 | 0.81 | DRD2 (0.50) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL2599491 | 0.81 | DRD2 (0.50) | TSHRPARP1HTR2CHTR2ASLC6A4 | |
| SCHEMBL15154774 | 0.81 | DRD2 (0.50) | TSHRPARP1HTR2CHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1757584-A1 | Heterocyclic substituted amides, their production and their use | Abbott GmbH & Co. KG (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-5658904-A | COGNITION ACTIVATORS; BRAIN DISORDERS; ALZHEIMER*S DISEASE | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5612381-A | 1,2-ethanediol derivative and salt thereof process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | TSHR 3008/4885PARP1 1343/4885HTR2C 2272/4885 |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | TSHR 670/4885PARP1 2215/4885HTR2C 147/4885 |
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | TSHR 299/4885PARP1 3970/4885HTR2C 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.